21 results about "Cancer targeting" patented technology

Disclosed are: an albumin-binding prodrug that can stably and selectively bind to albumin capable of targeting cancer while also stably binding to drugs; an albumin-drug conjugate in which the albumin-binding prodrug is bound to albumin; a method for preparing the albumin-drug conjugate; and a pharmaceutical composition for preventing or treating cancer, comprising the albumin-binding prodrug or the albumin-drug conjugate.

Recombinant polynucleotides and vectors containing an engineered (artificial) exon-intron-exon gene structure in a transgene are provided, which undergoes splicing when it is expressed in a target cell.

Provided herein is a composition comprising, a cell, comprising nucleic acids encoding a chimeric antigen receptor (CAR) and one or more of signaling proteins selected from K13-vFLIP, MC159-vFLIP, cFLIP-L, cFLIP-p22, HTLV1-Tax and HTLV2-Tax, wherein the CAR comprises an a) extracellular antigen specific domain, b) a transmembrane domain and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); wherein c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more co-stimulatory domains. Also provided herein are methods for treating diseases using the compositions described herein. Further provided herein is a kinase inhibitor for use in therapeutic methods described herein.

The present invention relates to a novel extracellular vesicle linked to an anti-TfR1 antibody and to a use thereof. An extracellular vesicle, according to one aspect, exhibits excellent delivery capability to tumor cells and activates immune cells, thereby being effectively usable as a targeted anticancer therapeutic not limited to specific cancer types.

To provide a method for treating the target cancer. [Solution] A method for treating a target cancer, comprising administering a bispecific antibody having binding specificity to EGFR and HER3 and a therapeutic agent to the target, wherein the therapeutic agent includes a tyrosine kinase inhibitor (TKI), an alkylating agent, an antimetabolite, a microtubule inhibitor, an anti-cancer antibiotic, a topoisomerase inhibitor, a chemoprotective agent, or a combination thereof.

Provided herein are methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity of ZSCAN4 in cancer cells in the subject, thereby treating the cancer.

The application discloses a spiro derivative as a WRN helicase inhibitor and application thereof. The spiro derivative has better WRN helicase inhibiting activity, can be used for inhibiting the growth of microsatellite instability (MSI) tumor cells by inhibiting WRN to cause high levels of DNA double-strand breaks (DSB) in the MSI cells, can be used for preventing and / or treating related cancers, especially colorectal cancer, gastric cancer, ovarian cancer and endometrial tumor, can fill the gap of specific MSI typing cancer targeting drugs, and has very good application prospect and value in the medical field.

The present invention relates generally to antibodies and antigen-binding fragments thereof, in particular those targeting cancer- associated antigens, compositions comprising the same, and methods and uses thereof for detecting cancer-associated antigens in tissues, including prostate cancer tissues. Also provided herein are methods for detecting prostate cancer in a subject, methods for detecting and measuring the severity of prostate cancer in a subject, methods for monitoring the progression of prostate cancer in a subject, methods for determining the likelihood of the presence of prostate cancer in a subject, methods for identifying a subject suffering from prostate cancer who is likely to respond to cancer therapy, methods for predicting the risk of recurrence of prostate cancer in a subject following treatment with a cancer therapy, methods for treating prostate cancer in a subject, methods of stratifying a subject for prostate cancer therapy, uses of anti-cancer agent in the manufacture of a medicament for treating prostate cancer in a subject, and an anti-cancer agent for use in the treatment of prostate cancer in a subject, based upon the detection of specific protein biomarkers with the antibodies described herein. Also contemplated are immunoassays, including immunohistochemistry (IHC) and immunofluorescence (IF), to detect specific protein biomarkers in biological samples. The preferred biomarkers include endosomal proteins, such as Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL1), sortilin-1 (SORT1), Syndecan-1 (SDC1).

Disclosed herein are multivalent, multispecific single-chain antibodies having specificity for four antigens selected from the group consisting of EGFR, PD-L1, HSA, CD28, CD3E, OX-40, CD40, 4-1BB, LAG3, and CD16A.

The present application relates to methods and uses of conjugates comprising antitumor agents (e.g., chemotherapeutic agents) conjugated to peptide compounds targeting Sortilin-expressing cancer stem cells (CSCs), in embodiments for the treatment of poor prognosis cancers refractory to standard antitumor therapies associated the presence of Sortilin-expressing CSCs, and for preventing or treating cancer relapse or recurrence.

To provide a structural optimization method for improving the therapeutic performance of radionuclide therapy targeting peptide receptors against cancer. [Solution] In a specific embodiment, the present invention provides formula I for cancer treatment: TLX This provides a cancer targeting conjugate containing and a method for using the same. T is an SST2R targeting ligand, L is a linker, X is a chelating agent. In one embodiment, the present invention relates to a novel chelating agent which is 1,4,7,10-tetraazacyclododecane-7-acetamido-1,4,10-triacetic acid.

The present invention provides a peptide that specifically binds to cells constituting cancer, and a pharmaceutical composition containing the peptide. The present invention is a cancer targeting peptide containing a peptide that binds to cancer cells and that comprises one or more amino acid sequences, each identical to a partial region of a human protein selected from the group consisting of extracellular matrix-constituting proteins, transcriptional regulators, nuclear regulators, signaling pathway proteins, and RNA regulatory proteins. The partial region comprises 5-7 amino acid residues.

An isolated cancer-targeting peptide comprising at least two copies of the amino acid sequence PFLP (SEQ ID NO: 1) or PELF (SEQ ID NO: 2). A pharmaceutical composition for treating cancer is also disclosed. The composition comprises the isolated cancer-targeting peptide and an anti-cancer agent. A bispecific anti-cancer antibody comprising the isolated cancer-targeting peptide and an antigen-binding peptide that stimulates T cell activity is also disclosed. A method for treating cancer by administering a pharmaceutical composition or a bispecific anti-cancer antibody is provided. A method for diagnosing cancer by administering a radionuclide-labeled cancer-targeting peptide to an individual and imaging the location of the radionuclide is also provided.

A compound derivative is provided, where R in the compound of formula A is 4-methylpiperazine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

The present invention relates to a genetic material carrier for transdermal delivery and a composition for preventing or treating cancer, comprising same. The genetic material carrier according to the present invention can promote the transdermal delivery of a genetic material and target cancer cells and has appropriate nano-size distribution and minimum non-specific cytotoxicity, by coating, with hyaluronic acid (HA), cationic solid lipid nanoparticles (CSLNs) that carry angiogenesis-inhibiting siVEGF, and thus can be used as a novel transdermal drug carrier for targeted cancer therapy.

The invention relates to new methods and approaches for the treatment of cancers, particularly cancers expressing TP53 mutations, comprising the administration of a Sting agonist, and either an anti-cancer immunotherapy, or a TP53 targeting cancer therapy.

The present disclosure relates to combination cancer therapies targeting CD38 and TGF-β using antibodies specific for these targets. Also provided are compositions useful in the therapies.

The present invention relates to uses of an anti-hGDF-15 antibody for the treatment of cancer in a patient in combination with a cancer antigen-targeted drug conjugate, such as an antibody-drug conjugate, that induces cancer cell stress.

A method and system for performing online adapted radiotherapy are provided using combined ultrasound and ionizing radiation induced acoustic imaging (iRAI) computed tomography imaging techniques that can be used for measurement of low to ultrahigh dose deliveries (>40 Gy / s). Multiplexed transducers detect US and iRAI signals allowing for anatomical / functional imaging and radiation mapping with absolute dosimetry measurements of a region of interest during a radiotherapy session. Corrections to radiation dosage intensities and locations is determined and provided as feedback to a radiation source to improve the accuracy of applied radiation dosages intra- or inter-radiotherapy treatment sessions preventing the irradiation of healthy tissues and ensuring the accurate delivery of radiation to a tumor or region of interest.

A fusion nanoprotein is provided wherein TRAIL with a trimer structure is conjugated to a human ferritin monomer fragment and exhibits enhanced cancer targeting using a cancer-targeting peptide. The fusion protein effectively targets cancer cells when injected into a blood vessel, leading to TRAIL-induced cancer cell death. This fusion nanoprotein addresses key challenges of TRAIL proteins by improving their stability and reducing off-target effects through stable delivery of TRAIL trimers specifically to cancer tissues. The enhanced stability and targeted delivery properties make this fusion protein a promising candidate for development as an anticancer therapeutic agent.

A composition for detecting ICAM1 protein comprising the anti-ICAM1 antibody of the present invention can selectively detect the protein by recognizing the N-glycan of ICAM1 that is cancer cell-specifically modified. The composition for detecting ICAM1 protein comprising an anti-ICAM1 antibody according to the present invention can selectively detect the corresponding protein by recognizing the N-glycan of ICAM1 that is cancer cell-specifically modified. In particular, the anti-ICAM1 antibody contained in the composition specifically recognizes and binds to a structure in which sialic acid residues at the N-glycan terminal linked to the N130 asparagine residue of ICAM1 are reduced or deficient, that is, a hyposialylated glycosylation pattern. By targeting a glycosylation pattern appearing only in cancer cells, the antibody provides high therapeutic stability due to low non-specific binding to normal cells. Accordingly, the present invention offers an anti-ICAM1 antibody that precisely targets a cancer-specific glycan pattern and a novel immune-oncology therapeutic strategy based thereon, thereby overcoming limitations of existing anticancer agents and providing enhanced cancer treatment effects.